Amylin: Pharmacology, Physiology, and Clinical Potential.
about
Differential effects of Calca-derived peptides in male mice with diet-induced obesitySubclinical Diabetes.Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons.Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.An allosteric role for receptor activity-modifying proteins in defining GPCR pharmacology.Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development.In vivo Efficacy and Pharmacokinetics of Optimized Apidaecin Analogs.Amylin-mediated control of glycemia, energy balance, and cognition.Na,K-ATPase regulation in skeletal muscle.The New Biology and Pharmacology of Glucagon.Amylin Acts in the Lateral Dorsal Tegmental Nucleus to Regulate Energy Balance Through Gamma-Aminobutyric Acid Signaling.Eating disorders: from bench to bedside and back.Pathophysiology of Migraine: A Disorder of Sensory Processing.Amylin.Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes.Reply to comment on: A second trigeminal CGRP receptor: function and expression of the AMY1 receptorHuman amylin proteotoxicity impairs protein biosynthesis, and alters major cellular signaling pathways in the heart, brain and liver of humanized diabetic rat model in vivo.Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25.N-Glycosylation of Asparagine 130 in the Extracellular Domain of the Human Calcitonin Receptor Significantly Increases Peptide Hormone Affinity.Modeling energy intake and body weight effects of a long-acting amylin analogue.RampDB: a web application and database for the exploration and prediction of receptor activity modifying protein interactions.The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc).Amylin in Alzheimer's disease: Pathological peptide or potential treatment?KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.Amylin - Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.Localization of amylin-like immunoreactivity in the striped velvet gecko pancreas.CGRP receptor antagonist activity of olcegepant depends on the signalling pathway measured.Islet Amyloid Polypeptide Membrane Interactions: Effects of Membrane Composition.CGRP and its receptors.Mapping the calcitonin receptor in human brain stem.Relationship of Type 2 Diabetes to Human Brain Pathology.Amylin Selectively Signals onto POMC Neurons in the Arcuate Nucleus of the Hypothalamus.Targeting dysfunctional beta-cell signaling for the potential treatment of type 1 diabetes mellitus.Ablation of somatostatin cells leads to impaired pancreatic islet function and neonatal death in rodents.Evolutionary Adaptation and Amyloid Formation: Does the Reduced Amyloidogenicity and Cytotoxicity of Ursine Amylin Contribute to the Metabolic Adaption of Bears and Polar Bears?
P2860
Q33860361-78712533-173D-4EBA-9772-F5A69CFF623DQ34556500-17BF8B33-3C76-43E9-A32F-3F77E3F9B8D0Q35889726-706CDB35-3D2A-40DC-833D-B82BF7C8AEE1Q36884693-2D94D332-D921-4E0A-8402-C2FBBA5B8365Q36907408-DD5420E7-C76C-46A8-86F4-24B7C87A7225Q36941265-CE0D4BD4-5ADE-470F-B1A1-173DFA73D226Q37710376-DA8C5F66-7DF0-43CE-AC34-33EA5E4D7D0DQ38753342-F206BAD9-8817-497E-BC38-C0E2F3D910A1Q38831589-73F62145-4C55-4F91-AFC6-6F8D1DB3B057Q38919742-8C3DBFB2-A6B6-443E-BE47-F2DD735A97A1Q38942152-DE6BAB92-9B90-4B75-B9F0-21626CF54B79Q38959757-E5BFDC20-253E-4A1A-B3FB-51A1A5777D51Q39127073-D3E1726A-3334-4C6D-849E-935BE3BF1444Q39293507-262443DD-1702-4453-831E-64EAAEF8043CQ39320824-5D623E1E-4DFA-465D-BE0D-3653102FDDB7Q39413453-A24F09BC-3901-4233-BC85-74FC06FC07F3Q39814264-95763115-CBB4-4A2A-8FBB-92BEF6CAC2A9Q41197182-CBC20487-3B4E-4D03-9BE9-670731343492Q46277281-2633C8B3-BE92-43B2-AB8C-274EF116C5F6Q46350132-F5C7EE6D-8F5B-410B-9EAA-74450BE3018BQ47175680-55D9002A-8F12-481A-9E64-B5B7EE3BF5C6Q47236545-E1EBEC25-FCD0-429C-86FE-96A765C62D70Q47315052-AD9F7C8E-8BE3-4792-A4C5-FD25081DFDFBQ47322028-1D79376C-9C8C-4E01-81EA-031A8AF95389Q47323414-A6BBA0F4-4D49-4B0E-86FA-128F8E25B5D8Q47371506-7DF5580F-27DF-4C99-AA78-746F57FDC0B3Q47874734-081E31AB-DA57-4108-9562-C63205D57193Q47976301-210D982E-2E4F-4CAC-8E8B-EAA857679D2DQ48092573-74416BB9-5D8F-4C9D-A0F6-92A496CDFC7AQ48198655-79272D5D-730F-4257-8FF5-9BB608ED8CECQ48881416-DF858CC5-830E-4538-87EF-BB91979B6B53Q50103147-5FE15FEB-AF8F-424B-A129-96AF9DCE92A2Q50422426-8EB7C437-DB6D-43C7-9EA6-581F4922ABE4Q52674501-64694E13-2F68-4B6A-B7A3-9A338D587196Q55104419-2D968C15-17A5-4AE5-816C-EB1274BF4CA0Q55404538-66B1E36F-F05A-4B06-B382-F8E96D27E9CA
P2860
Amylin: Pharmacology, Physiology, and Clinical Potential.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Amylin: Pharmacology, Physiology, and Clinical Potential.
@en
type
label
Amylin: Pharmacology, Physiology, and Clinical Potential.
@en
prefLabel
Amylin: Pharmacology, Physiology, and Clinical Potential.
@en
P2093
P356
P1476
Amylin: Pharmacology, Physiology, and Clinical Potential.
@en
P2093
David G Parkes
Jonathan D Roth
Steve Chen
P304
P356
10.1124/PR.115.010629
P577
2015-07-01T00:00:00Z